LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation

Atherosclerosis

Volumn 245, Issue , 2016, Pages 200-211

  Afonso, Pauline ^a,c,h   Auclair, Martine ^a,c,h   Boccara, Franck ^a,c,d   Vantyghem, Marie Christine ^f   Katlama, Christine ^b,c,g   Capeau, Jacqueline ^a,c,e,h   Vigouroux, Corinne ^a,c,d,h   Caron Debarle, Martine ^a,c,h  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL TENON   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h ICAN   (France)

Author keywords

Atherosclerosis; Osteogenic transdifferentiation; Prelamin A; Senescence; Vascular smooth muscle cells; ZMPSTE24

Indexed keywords

ACETYLCYSTEINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MARAVIROC; METALLOPROTEASE ZMPSTE24; METALLOPROTEINASE; MICRORNA 141; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PRAVASTATIN; PRELAMIN A; PROTEIN DERIVATIVE; RALTEGRAVIR; UNCLASSIFIED DRUG; DNA; LAMIN A; LMNA PROTEIN, HUMAN; MEMBRANE PROTEIN; ZMPSTE24 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; LIPODYSTROPHY; LMNA GENE; MARKER GENE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; VASCULAR SMOOTH MUSCLE CELL; BIOSYNTHESIS; CELL AGING; CELL CULTURE; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR CALCIFICATION;

CELL AGING; CELLS, CULTURED; DNA; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; HIV PROTEASE INHIBITORS; HUMANS; LAMIN TYPE A; LIPODYSTROPHY; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR CALCIFICATION;

EID: 84951761244     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.012     Document Type: Article

References (61)

1. Mattout A., Dechat T., Adam S.A., Goldman R.D., Gruenbaum Y. Nuclear lamins, diseases and aging. Curr. Opin. Cell Biol. 2006, 18:335-341.
2. Fong L.G., Ng J.K., Meta M., Cote N., Yang S.H., Stewart C.L., et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18111-18116.
3. Glynn M.W., Glover T.W. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 2005, 14:2959-2969.
4. Fong L.G., Frost D., Meta M., Qiao X., Yang S.H., Coffinier C., et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006, 311:1621-1623.
5. Eriksson M., Brown W.T., Gordon L.B., Glynn M.W., Singer J., Scott L., et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.
6. Cadinanos J., Varela I., Lopez-Otin C., Freije J.M. From immature lamin to premature aging: molecular pathways and therapeutic opportunities. Cell Cycle 2005, 4:1732-1735.
7. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Amiel J., Boccaccio I., et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.
8. Varela I., Cadinanos J., Pendas A.M., Gutierrez-Fernandez A., Folgueras A.R., Sanchez L.M., et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005, 437:564-568.
9. Barrowman J., Michaelis S. ZMPSTE24, an integral membrane zinc metalloprotease with a connection to progeroid disorders. Biol. Chem. 2009, 390:761-773.
10. Caron M., Auclair M., Donadille B., Bereziat V., Guerci B., Laville M., et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ. 2007, 14:1759-1767.
11. Capanni C., Mattioli E., Columbaro M., Lucarelli E., Parnaik V.K., Novelli G., et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum. Mol. Genet. 2005, 14:1489-1502.
12. Caux F., Dubosclard E., Lascols O., Buendia B., Chazouilleres O., Cohen A., et al. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J. Clin. Endocrinol. Metab. 2003, 88:1006-1013.
13. Capell B.C., Collins F.S., Nabel E.G. Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ. Res. 2007, 101:13-26.
14. Olive M., Harten I., Mitchell R., Beers J.K., Djabali K., Cao K., et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arteriosclerosis, Thrombosis, Vasc. Biol. 2010, 30:2301-2309.
15. Bidault G., Garcia M., Vantyghem M.C., Ducluzeau P.H., Morichon R., Thiyagarajah K., et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2162-2171.
16. Ragnauth C.D., Warren D.T., Liu Y., McNair R., Tajsic T., Figg N., et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010, 121:2200-2210.
17. Liu Y., Drozdov I., Shroff R., Beltran L.E., Shanahan C.M. Prelamin a accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells. Circ. Res. 2013, 112:e99-e109.
18. Micheletti R.G., Fishbein G.A., Fishbein M.C., Singer E.J., Weiss R.E., Jeffries R.A., et al. Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol. 2009, 18:28-36.
19. Guaraldi G., Zona S., Orlando G., Carli F., Ligabue G., Fiocchi F., et al. Human immunodeficiency virus infection is associated with accelerated atherosclerosis. J. Antimicrob. Chemother. 2011, 66:1857-1860.
20. Boccara F., Lang S., Meuleman C., Ederhy S., Mary-Krause M., Costagliola D., et al. HIV and coronary heart disease: time for a better understanding. J. Am. Coll. Cardiol. 2013, 61:511-523.
21. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
22. Coffinier C., Hudon S.E., Farber E.A., Chang S.Y., Hrycyna C.A., Young S.G., et al. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13432-13437.
23. Hudon S.E., Coffinier C., Michaelis S., Fong L.G., Young S.G., Hrycyna C.A. HIV-protease inhibitors block the enzymatic activity of purified Ste24p. Biochem. Biophys. Res. Commun. 2008, 374:365-368.
24. Lefevre C., Auclair M., Boccara F., Bastard J.P., Capeau J., Vigouroux C., et al. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2611-2620.
25. Bonello-Palot N., Simoncini S., Robert S., Bourgeois P., Sabatier F., Levy N., et al. Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment. Atherosclerosis 2014, 237:45-52.
26. Auclair M., Afonso P., Capel E., Caron-Debarle M., Capeau J. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir. Ther. 2014, 19(8):773-782.
27. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J. Biol. Chem. 2008, 283:15319-15327.
28. Kalra S.S., Shanahan C.M. Vascular calcification and hypertension: cause and effect. Ann. Med. 2012, 44(Suppl. 1):S85-S92.
29. Demer L.L., Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2014, 34:715-723.
30. Burton D.G., Giles P.J., Sheerin A.N., Smith S.K., Lawton J.J., Ostler E.L., et al. Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification. Exp. Gerontol. 2009, 44:659-665.
31. Burton D.G., Matsubara H., Ikeda K. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells. Exp. Gerontol. 2010, 45:819-824.
32. Kramer C.K., Zinman B., Gross J.L., Canani L.H., Rodrigues T.C., Azevedo M.J., et al. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ 2013, 346. f1654.
33. Guaraldi G., Zona S., Alexopoulos N., Orlando G., Carli F., Ligabue G., et al. Coronary aging in HIV-infected patients. Clin. Infect. Dis. 2009, 49:1756-1762.
34. Post W.S., Budoff M., Kingsley L., Palella F.J., Witt M.D., Li X., et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann. Intern Med. 2014, 160:458-467.
35. Lang S., Mary-Krause M., Cotte L., Gilquin J., Partisani M., Simon A., et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French hospital database on HIV ANRS cohort CO4. Arch. Intern Med. 2010, 170:1228-1238.
36. Worm S.W., Sabin C., Weber R., Reiss P., El-Sadr W., Dabis F., et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. J. Infect. Dis. 2010, 201:318-330.
37. Decaudain A., Vantyghem M.C., Guerci B., Hecart A.C., Auclair M., Reznik Y., et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J. Clin. Endocrinol. Metab. 2007, 92:4835-4844.
38. Katlama C., Assoumou L., Valantin M.A., Soulie C., Duvivier C., Chablais L., et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J. Antimicrob. Chemother. 2014, 69:1648-1652.
39. Giachelli C.M. Vascular calcification mechanisms. J. Am. Soc. Nephrol. 2004, 15:2959-2964.
40. Yu K.R., Lee S., Jung J.W., Hong I.S., Kim H.S., Seo Y., et al. MicroRNA-141-3p plays a role in human mesenchymal stem cell aging by directly targeting ZMPSTE24. J. Cell Sci. 2013, 126:5422-5431.
41. Olsen P.H., Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev. Biol. 1999, 216:671-680.
42. Russell R.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
43. Caron M., Vigouroux C., Bastard J.-P., Capeau J. Adipocyte dysfunction in response to antiretroviral therapy : clinical, tissue and in-vitro studies. Curr. Opin. HIV AIDS 2007, 2:268-273.
44. Bereziat V., Cervera P., Le Dour C., Verpont M.C., Dumont S., Vantyghem M.C., et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am. J. Pathol. 2011, 179:2443-2453.
45. Chen L., Lee L., Kudlow B.A., Dos Santos H.G., Sletvold O., Shafeghati Y., et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003, 362:440-445.
46. Todorovic S., Milenkovic T.K.M., Zdravkovic D., Stajic N., Vukovic R. Atypical progeroid syndrome - case report. Horm. Res. 2012, 78:164.
47. Krimm I., Ostlund C., Gilquin B., Couprie J., Hossenlopp P., Mornon J.P., et al. The Ig-like structure of the C-terminal domain of lamin A/C, mutated in muscular dystrophies, cardiomyopathy, and partial lipodystrophy. Structure 2002, 10:811-823.
48. Stierle V., Couprie J., Ostlund C., Krimm I., Zinn-Justin S., Hossenlopp P., et al. The carboxyl-terminal region common to lamins A and C contains a DNA binding domain. Biochemistry 2003, 42:4819-4828.
49. Oldenburg A.R., Delbarre E., Thiede B., Vigouroux C., Collas P. Deregulation of fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes. Hum. Mol. Genet. 2014, 23:1151-1162.
50. Vadrot N., Duband-Goulet I., Cabet E., Attanda W., Barateau A., Vicart P., et al. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 2015, 24:2096-2109.
51. Quigley A., Dong Y.Y., Pike A.C., Dong L., Shrestha L., Berridge G., et al. The structural basis of ZMPSTE24-dependent laminopathies. Science 2013, 339:1604-1607.
52. Coffinier C., Hudon S.E., Lee R., Farber E.A., Nobumori C., Miner J.H., et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J. Biol. Chem. 2008, 283:9797-9804.
53. Monforte A., Reiss P., Ryom L., El-Sadr W., Dabis F., De Wit S., et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013, 27:407-415.
54. Podzamczer D., Andrade-Villanueva J., Clotet B., Taylor S., Rockstroh J.K., Reiss P., et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med. 2011, 12:374-382.
55. Menzaghi B., Ricci E., Carenzi L., Parruti G., Orofino G., Guastavigna M., et al. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA project). Biomed. Pharmacother. 2013, 67:293-298.
56. Arathoon E., Schneider S., Baraldi E., Lim P.L., Opravil M., Van De Casteele T., et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int. J. STD AIDS 2013, 24:12-17.
57. Orkin C., DeJesus E., Khanlou H., Stoehr A., Supparatpinyo K., Lathouwers E., et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013, 14:49-59.
58. Gordon L.B., Kleinman M.E., Miller D.T., Neuberg D.S., Giobbie-Hurder A., Gerhard-Herman M., et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16666-16671.
59. Young S.G., Yang S.H., Davies B.S., Jung H.J., Fong L.G. Targeting protein prenylation in progeria. Sci. Transl. Med. 2013, 5. 171ps3.
60. Bauer A.J., Banek C.T., Needham K., Gillham H., Capoccia S., Regal J.F., et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013, 61:1103-1110.
61. Perrin S., Cremer J., Faucher O., Reynes J., Dellamonica P., Micallef J., et al. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study. PLoS One 2012, 7. e53035.